On May 18, 2020, Moderna announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the NIAID. Immunogenicity data are available for the 25 ﾵg and 100 ﾵg dose level (ages 18-55) after two doses (day 43) and at the 250 ﾵg level (ages 18-55) after one dose (day 29). Dose dependent increases in immunogenicity were seen across the three dose levels, and between prime and boost within the 25 ﾵg and 100 ﾵg dose levels.